DLIMI is now Signum

X

Medical adherence to glaucoma treatment

Predictors and long-term patterns of medical adherence to glaucoma treatment in Denmark

An observational registry study of 30,100 Danish patients with glaucoma

Resume

Self-treatment with glaucoma medication (eye drops) has been associated with adherence challenges. Poor adherence results in worse outcomes in terms of visual field loss.
The study aims to analyze patterns in medication adherence among Danish patients with glaucoma. It focuses on predictors of adherence, long-term adherence patterns, and the economic impact on society due to poor adherence.


We conducted a register-based study with 30,100 patients with glaucoma followed for 10 years between 2000 and 2018. Glaucoma was identified from the Danish national registers through the diagnosis of Open Angle Glaucoma or redeemed prescriptions of glaucoma medication. We applied logistic regression to estimate patient characteristics related to adherence. We estimated healthcare costs using diagnosis-related group fees.


Our results showed lower adherence in the first year(s) of treatment among men, younger individuals and those with a positive Charlson Comorbidity Index (CCI) score.
Adherence in the first year and in the first two years was associated with adherence in the fifth as with adherence in the 10th year with slightly lower estimates.
Being medical adherent was related to higher glaucoma medication costs after 5 and 10 years compared with being poorly adherent, while poor adherence was associated with a marked increase in long-term costs for hospital contacts.

Conclusion

In conclusion, older patients, women, and those with low comorbidity scores adhere better to glaucoma treatment. Adherence in the first years of treatment may be a good predictor for future adherence. Patients with poor adherence incur higher long-term costs for society due to increased hospital contacts.

Link: Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark—an observational registry study of 30 100 Danish patients with glaucoma | BMJ Open Ophthalmology

For more information, please contact

Anne Cathrine Falch-Jørgensen. employee at Signum, chief advisor

Anne Cathrine Falch-Jørgensen

Chief Advisor, Real World Evidence


acfj@signumlifescience.com

+45 61 776 975